Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Instituto Valenciano de Infertilidad, Spain |
---|---|
Information provided by: | Instituto Valenciano de Infertilidad, Spain |
ClinicalTrials.gov Identifier: | NCT00625950 |
Dopamine agonists, such as quinagolide, are able to act on the VEGFR-2 blocking antibodies, diminishing Vascular Endothelial Growth Factor effect on angiogenesis in human endometriotic lesions.
Condition | Intervention | Phase |
---|---|---|
Hyperprolactinemia Endometriosis |
Procedure: ENDOMETRIAL BIOPSY |
Phase IV |
Study Type: | Interventional |
Study Design: | Health Services Research, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Efficacy Study |
Official Title: | Effect of Treatment With Agonist Dopaminergics on Endometriosic Lesions. |
Estimated Enrollment: | 5 |
Study Start Date: | February 2008 |
Study Completion Date: | May 2008 |
Primary Completion Date: | April 2008 (Final data collection date for primary outcome measure) |
Ages Eligible for Study: | 18 Years to 37 Years |
Genders Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Responsible Party: | Instituto Valenciano de Infertilidad, Spain ( Prof. Dr. Antonio Pellicer ) |
Study ID Numbers: | VLC-AP-10208-208-1 |
Study First Received: | February 20, 2008 |
Last Updated: | January 9, 2009 |
ClinicalTrials.gov Identifier: | NCT00625950 |
Health Authority: | Spain: Ethics Committee |
Hyperprolactinemia Endometriosis laparoscopy angiogenesis, VEGF |
Genital Diseases, Female Hypothalamic Diseases Quinagolide Dopamine Pituitary Diseases Galactorrhoea-Hyperprolactinaemia |
Endocrine System Diseases Central Nervous System Diseases Endometriosis Hyperprolactinemia Endocrinopathy Brain Diseases |
Hyperpituitarism Nervous System Diseases |